(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, announced late Tuesday the pricing of public offerings of common stock, pre-funded warrants and convertible senior notes for total proceeds of approximately $1.0 billion.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.